Inari Medical (Nasdaq:NARI) announced this week that Drew Hykes will succeed Bill Hoffman as the company’s CEO.
Hykes, who currently serves as COO at the venous-specific devices company, will succeed Hoffman, effective Jan. 1, 2023. He will also join Inari’s board, while Hoffman will continue to serve on the board as well.
“Drew is a talented leader, and he is the single best problem solver I’ve ever seen. More important, he is committed to the beautiful simplicity of our mission to impact the lives of our patients and their families in extraordinary ways, and to take care of our people along the way,” Hoffman said in a news release. “Drew has established the scalable and repeatable systems that have produced best-in-class growth in patient treatments and revenue, and he has developed the cross-functional processes that have resulted in the explosion of new products and new markets we are just beginning to see. His leadership style and his skill set could not be better suited to the complexities that our next phase of growth will require. I am personally excited to have a front row seat to watch him lead the best team in the medical device space.”
Hykes has been at Inari since 2017, having joined as chief commercial officer. He has served in the COO role since 2020.
Before Inari, Hykes served in a number of leadership roles at public and private medical device companies, Inari said, with broad functional, geographic and sector experience. His decades of experience in the space will contribute to Inari’s mission of effectively treating venous thromboembolism, the company added.
“I am incredibly humbled to be named as Inari’s next CEO,” said Hykes. “Inari has undergone tremendous growth and change since I joined in 2017. From a venture-backed, pre-commercial startup to an established public company with over 1,000 clot warriors, increasingly broad-based capabilities, and a shared ambition to change lives in the venous space and beyond.
“Despite all these changes, thanks to Bill’s leadership, we have maintained an unwavering commitment to our patients, our people and to big ideas. I couldn’t be more committed to these same ideals, nor more enthusiastic about this next phase of our growth.”